Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2026-03-31 00:00:00 ET · period of report 2026-03-06 · accession 0002001011-26-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-31 | 2026-03-06 | LGND | LAMATTINA JOHN L | Dir | M - OptEx | $114.15 | +2,161 | 32.9K | +7% | +$246.7K |
| D | 2026-03-31 | 2026-03-06 | LGND | LAMATTINA JOHN L | Dir | S - Sale+OE | $200.76 | -2,161 | 30.7K | -7% | -$433.8K |
| D | 2026-03-31 | 2026-03-06 | LGND | LAMATTINA JOHN L | Dir | M - OptEx | $0.00 | -2,161 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-06 | M | A | 2,161 | $114.15 | 32,885 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-06 | S | D | 2,161 | $200.76 | 30,724 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-03-06 | M | D | 2,161 | $0.00 | 0 | D | $114.15 · — to 2028-06-19 | 2,161 Common Stock | (F1) This Option was previously reported as a Grant of 2,474 shares, which vested in full on June 6, 2019, at an exercise price of $195.91 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |